TN
Therapeutic Areas
Alpha Fusion Pipeline
| Drug | Indication | Phase |
|---|---|---|
| af-001 (TAH-1005) | Thyroid Cancer (Radioiodine-Refractory) | Phase 1 |
| af-001 | Thyroid Cancer (Radioiodine-Naïve) | Phase 1 |
| af-002 (PSW-1025) | Prostate Cancer (Refractory) | IND-enabling |
| af-003 | Pan-Cancer | IND-enabling |
| Tanabe-Veneno Program | Undisclosed | Exploratory |
| In-house Program | Undisclosed | Exploratory |